PTAB challenges

Proceedings overview

US patent 11014982 currently has one active AIA trial proceeding on file, IPR2026-00256, which is in a pending status. No claims have been invalidated or sustained by the PTAB yet. This means the patent's claims remain untested and susceptible to challenge, offering a defendant potential avenues for invalidation.

IPR2026-00256 — Accord BioPharma, Inc. et al. v. Janssen Biotech Inc

• Type: Inter Partes Review
• Filed: 2026-03-20
• Status: Pending – The proceeding has been filed and is awaiting a decision on institution.
• Judge panel: Information not yet publicly available at this stage.
• Petition grounds: Details regarding specific claims, prior art, and statutory bases (§ 102 / § 103 / § 112) are not yet public as the petition itself is not provided in the prompt. A typical IPR challenges patentability based on anticipation (§ 102) and/or obviousness (§ 103) over patents or printed publications.
• Institution decision: Not yet issued. The statutory deadline for the institution decision is typically six months from the filing date of the petition, which would be around September 20, 2026.
• Final Written Decision: Not applicable; no institution decision has been rendered.
• Settlement / termination: Not applicable; the proceeding is pending institution.
• Appeal: Not applicable; no Final Written Decision has been issued.
• Defensive value: This active IPR proceeding indicates that at least one party (Accord BioPharma, Inc. et al.) believes there are grounds to challenge the patentability of claims in US11014982. A defendant facing assertion of this patent should monitor this proceeding closely, as institution or eventual invalidation of claims would significantly weaken the patent owner's position.

Strategic summary

Currently, all claims of US11014982 remain UNTESTED by the PTAB, as the single IPR proceeding (IPR2026-00256) is still in the pre-institution phase. There are no claims that have been CANCELED or SUSTAINED by the PTAB to date.

The estoppel landscape has not yet been formed for this patent. Should IPR2026-00256 be instituted and proceed to a Final Written Decision, the petitioner (Accord BioPharma, Inc. et al.) and its privies would be estopped under § 315(e)(2) from asserting in future district court or ITC actions any invalidity ground they raised or reasonably could have raised in the IPR concerning the claims that went to final judgment. For other potential defendants, the prior art grounds raised by Accord BioPharma, Inc. et al. would likely still be available, unless they are in privy with the petitioner.

There is no discernible pattern of multiple IPR filings on this patent, as only one is currently recorded. There is no information yet on the patent owner's (Janssen Biotech Inc) aggressive pursuit of PTAB appeals, as no FWD has been issued. There is no indication of a defensive aggregator like Unified Patents being involved based on the provided petitioner information.

Recommended next steps

As IPR2026-00256 is pending institution, a key milestone to watch is the institution decision deadline around September 20, 2026. This decision will determine which, if any, claims proceed to trial. Parties facing assertion of US11014982 should monitor the PTAB's decision to institute, as this will clarify which specific claims are being challenged and on what grounds. Access to the petition would provide insight into the specific prior art and arguments being made against the patent.